Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests and real-world data will be presented at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022), hosted by the International Association for the Study of Lung Cancer, August 6-9 in Vienna, Austria. Among the 10 abstracts are oral presentations and posters highlighting the use of Guardant360 to help physicians inform treatment decisions, GuardantOMNI to advance cancer therapy trials, and GuardantINFORM for targeted drug development to improve outcomes for patients with lung cancer.

“We look forward to sharing new data at WCLC that demonstrate the utility of our liquid biopsy tests and datasets to create more accurate tumor profiles and impact outcomes for lung cancer patients around the world,” said Helmy Eltoukhy, Guardant Health co-CEO. “The data from retrospective and real-world analyses will show how blood-based tests provide critical insights into tumor evolution and treatment resistance throughout each lung cancer patient’s treatment journey and contribute more broadly to further developing the field of thoracic oncology.”

Full List of Presentations:

Guardant360

• Clinical and molecular profile of patients with non-small cell lung cancer (NSCLC) with incidental pathogenic germline variants detected in cfDNA (oral)
• Patterns of KEAP1 genomic co-alterations in advanced lung cancer as identified by plasma-based genotyping (e-poster)
• Germline HRR mutations in metastatic NSCLC and impact on progression-free survival: A single-center retrospective study (e-poster)
• Targetable alterations in non-small cell lung cancer according to age and sex (e-poster)
• Liquid biopsies first to make treatment decisions in patients with metastatic non-small cell lung cancer (NSCLC) (e-poster)
• Landscape of EGFR extracellular domain mutations in advanced non-small cell lung carcinoma (e-poster)
• The patient impact of liquid biopsy – health-related quality of life in patients undergoing liquid biopsy for advanced non-small cell lung cancer (e-poster)

GuardantINFORM

• Impact of germline BRCA1/2 alterations on EGFR mutant advanced non-small cell lung cancer outcomes (e-poster)
• Real-world landscape of EGFR C797X mutation as a resistance mechanism to osimertinib in non-small cell lung cancer (oral)

GuardantOMNI

• Durvalumab + olaparib vs. durvalumab alone as maintenance therapy in metastatic NSCLC: Outcomes from the phase 2 ORION study (poster)

About Guardant Health